Sign in Subscribe
Vaccines

George Washington University to Participate in COVID-19 Vaccine Trial

Strategic Insights

— 1 min read

Scientists at the George Washington University (GW) have been selected to participate in a clinical trial for an experimental COVID-19 vaccine, aiming to develop new tools to prevent the disease caused by the novel coronavirus. The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), will be conducted at approximately 90 sites in the United States as part of the COVID-19 Prevention Network (CoVPN). Researchers at GW aim to enroll 500 participants, with at least one-quarter being 65 or older, or younger than 65 with comorbidities. The trial will test the safety and efficacy of the mRNA-1273 vaccine, co-developed by NIAID scientists and Moderna, Inc.

Key Takeaways:

  • GW will participate in a Phase 3 clinical trial of the mRNA-1273 vaccine, co-developed by NIAID scientists and Moderna, Inc.
  • The trial aims to enroll 500 participants at GW out of 30,000 volunteers nationwide.
  • At least one-quarter of the participants will be 65 or older, or younger than 65 with comorbidities.
  • Participants will receive two injections, spaced one month apart, with half receiving a saline placebo as a control measure.
  • Researchers will follow up with participants for two years after the second dose of the vaccine to monitor symptoms and side effects.
  • The study will be conducted in partnership with the Milken Institute School of Public Health (Milken Institute SPH) and the NIH-funded GW HIV Prevention Trials Network clinical research site.
  • Manya Magnus, PhD, MPH, a professor of epidemiology at Milken Institute SPH, will support recruitment and data quality efforts.

Statistics:

  • 500 participants will be enrolled at GW out of 30,000 volunteers nationwide.
  • At least 125 participants will be 65 or older.
  • At least 125 participants will be younger than 65 with comorbidities.
  • 500 participants will receive two injections, spaced one month apart.
  • 250 participants will receive a saline placebo as a control measure.
  • Researchers will follow up with participants for two years after the second dose of the vaccine.

Sources:

  • The George Washington University
  • National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)
  • COVID-19 Prevention Network (CoVPN)
  • Moderna, Inc.
  • Milken Institute School of Public Health (Milken Institute SPH)
  • HIV Prevention Trials Network clinical research site.

Read more